Cytek Biosciences reports preliminary 2025 revenue of approximately $201M
Cytek Biosciences (NASDAQ:CTKB), a leading provider of cell analysis solutions including its flagship Aurora and Northern Lights spectral flow cytometry platforms, announced preliminary, unaudited revenue expectations for the fourth quarter and full year ended December 31, 2025.





-640x358.jpg&w=3840&q=75)





-640x358.jpg&w=3840&q=75)




-640x358.jpg&w=3840&q=75)


-640x358.jpg&w=3840&q=75)



-640x358.jpg&w=3840&q=75)